An investigation on behalf of investors of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares over potential securities laws violations by BioCryst Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.
Investors who purchased shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) concerning whether a series of statements by BioCryst Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
BioCryst Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $17.33 million in 2013 to $13.61 million in 2014 and that its Net Loss increased from $30.11 million to $45.19 million
On October 8, 2015, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administeredBCX7353 in healthy volunteers successfully met all of its objectives. In a separate announcement BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX announced the completion of patient enrollment in OPuS-2: a Clinical Trial of Avoralstat in Patients With HAE
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) declined from $16.39 per share to as low as $8.01 per share on October 8, 2015.
On November 9, 2015, NASDAQ:BCRX shares closed at $10.13 per share.
Those who purchased shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com